PACIFIC BIOSCIENCES OF CALIFORNIA Business Summary

Pacific Biosciences of California, Inc. (PacBio) operates a high-margin razor-and-blade business model, generating revenue through the sale of advanced genomic sequencing systems and the recurring sale of proprietary consumables, including SMRT Cells and reagent kits. As of February 2026, the company has transitioned into a pure-play long-read sequencing provider following the strategic divestiture of its short-read sequencing assets. Its primary business segments are built around the flagship Revio and benchtop Vega platforms, which utilize Single Molecule, Real-Time (SMRT) technology to produce high-fidelity (HiFi) genomic data. The 2026 commercial rollout of SparkNex (SPRQ-Nx) chemistry further optimizes this model by significantly reducing per-genome costs and increasing throughput to maintain competitive parity. PacBio competes directly with Oxford Nanopore Technologies, Illumina, and 10x Genomics, positioning itself as the market leader in high-accuracy long-read sequencing for complex de novo assembly, structural variant detection, and clinical rare disease research. The leadership team is anchored by President and CEO Christian Henry, a veteran of the genomics industry who, as of early 2026, has assumed interim oversight of research, development, and operations to accelerate product execution. He is supported by Chief Financial Officer Jim Gibson, who joined in 2025 with a pedigree of scaling financial operations at Tesla and Apple, and Chief Operating Officer Mark Van Oene, who currently manages global sales and customer support. Technical innovation remains driven by Founder and CTO Dr. Stephen Turner, the primary architect of the company’s foundational SMRT technology. PacBio’s strategic trajectory is guided by a board of directors chaired by Dr. John Milligan, former CEO of Gilead Sciences, and includes Chris Smith, former CEO of NeoGenomics. The company continues to attract significant institutional interest from investors such as ARK Investment Management, reflecting its pivotal role in the global shift toward precision medicine and multi-omic analysis.